Home › Compare › FRSHY vs ABBV
FRSHY yields 2.05% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, FRSHY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FRSHY + ABBV for your $10,000?
China Jinmao Holdings Group Limited, an investment holding company, operates in real estate and hotel businesses in Mainland China. It operates in four segments: City and Property Development, Commercial Leasing and Retail Operations, Hotel Operations, and Others. The City and Property Development segment develops city complexes and properties, as well as develops land. The Commercial Leasing and Retail Operations segment engages in the leasing of office and retail commercial premises. This segment has twelve investment properties with an area of approximately 0.80 million square meters. The Hotel Operations segment provides hotel accommodation, and food and beverages services. This segment operates ten luxury hotels that offers 3,968 guest rooms. The Others segment offers property management, and design and decoration services, as well as operates an observation deck. The company also engages in technology and services business. It holds 334 projects of city operations and property development, commercial leasing and retail operations, and hotel operations. The company was formerly known as Franshion Properties (China) Limited and changed its name to China Jinmao Holdings Group Limited in September 2015. China Jinmao Holdings Group Limited was incorporated in 2004 and is based in Wan Chai, Hong Kong.
Full FRSHY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.